Limits...
The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases.

Butrous G - Glob Cardiol Sci Pract (2014)

Bottom Line: Phosphodiesterase inhibitors (PDE) can be used as therapeutic agents for various diseases such as dementia, depression, schizophrenia and erectile dysfunction in men, as well as congestive heart failure, chronic obstructive pulmonary disease, rheumatoid arthritis, other inflammatory diseases, diabetes and various other conditions.In this review we will concentrate on one type of PDE, mainly PDE5 and its role in pulmonary vascular diseases.

View Article: PubMed Central - PubMed

ABSTRACT
Phosphodiesterase inhibitors (PDE) can be used as therapeutic agents for various diseases such as dementia, depression, schizophrenia and erectile dysfunction in men, as well as congestive heart failure, chronic obstructive pulmonary disease, rheumatoid arthritis, other inflammatory diseases, diabetes and various other conditions. In this review we will concentrate on one type of PDE, mainly PDE5 and its role in pulmonary vascular diseases.

No MeSH data available.


Related in: MedlinePlus

The schematic diagram of the PDE5 monomer, the PDE5 enzyme in the cell is a homodimer, which means it is comprised of two identical units approximately equal in size (see Figure 7). Each monomer contains a carboxyl-terminal catalytic domain (left) with a special pocket to occupy cGMP (or PDE5 inhibitor) for the catalytic role of enzyme (arrow) the detail of the pocket is shown in Figure 6.The other half (to the right is regulatory domain with two allosteric binding pockets for cGMP the regulatory domain GAF-A (yellow) and GAF –B (green), and, a phosphorylation site.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4352681&req=5

fig5: The schematic diagram of the PDE5 monomer, the PDE5 enzyme in the cell is a homodimer, which means it is comprised of two identical units approximately equal in size (see Figure 7). Each monomer contains a carboxyl-terminal catalytic domain (left) with a special pocket to occupy cGMP (or PDE5 inhibitor) for the catalytic role of enzyme (arrow) the detail of the pocket is shown in Figure 6.The other half (to the right is regulatory domain with two allosteric binding pockets for cGMP the regulatory domain GAF-A (yellow) and GAF –B (green), and, a phosphorylation site.

Mentions: PDE5 enzyme in the cell is a homodimer, which means it is comprised of two identical units approximately equal in size. Each monomer contains a carboxyl-terminal catalytic domain, with a highly conserved zinc-binding motif, and regulatory domain with two allosteric binding pockets for cGMP, a phosphorylation site (Figure 5).6,25,27–29


The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases.

Butrous G - Glob Cardiol Sci Pract (2014)

The schematic diagram of the PDE5 monomer, the PDE5 enzyme in the cell is a homodimer, which means it is comprised of two identical units approximately equal in size (see Figure 7). Each monomer contains a carboxyl-terminal catalytic domain (left) with a special pocket to occupy cGMP (or PDE5 inhibitor) for the catalytic role of enzyme (arrow) the detail of the pocket is shown in Figure 6.The other half (to the right is regulatory domain with two allosteric binding pockets for cGMP the regulatory domain GAF-A (yellow) and GAF –B (green), and, a phosphorylation site.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4352681&req=5

fig5: The schematic diagram of the PDE5 monomer, the PDE5 enzyme in the cell is a homodimer, which means it is comprised of two identical units approximately equal in size (see Figure 7). Each monomer contains a carboxyl-terminal catalytic domain (left) with a special pocket to occupy cGMP (or PDE5 inhibitor) for the catalytic role of enzyme (arrow) the detail of the pocket is shown in Figure 6.The other half (to the right is regulatory domain with two allosteric binding pockets for cGMP the regulatory domain GAF-A (yellow) and GAF –B (green), and, a phosphorylation site.
Mentions: PDE5 enzyme in the cell is a homodimer, which means it is comprised of two identical units approximately equal in size. Each monomer contains a carboxyl-terminal catalytic domain, with a highly conserved zinc-binding motif, and regulatory domain with two allosteric binding pockets for cGMP, a phosphorylation site (Figure 5).6,25,27–29

Bottom Line: Phosphodiesterase inhibitors (PDE) can be used as therapeutic agents for various diseases such as dementia, depression, schizophrenia and erectile dysfunction in men, as well as congestive heart failure, chronic obstructive pulmonary disease, rheumatoid arthritis, other inflammatory diseases, diabetes and various other conditions.In this review we will concentrate on one type of PDE, mainly PDE5 and its role in pulmonary vascular diseases.

View Article: PubMed Central - PubMed

ABSTRACT
Phosphodiesterase inhibitors (PDE) can be used as therapeutic agents for various diseases such as dementia, depression, schizophrenia and erectile dysfunction in men, as well as congestive heart failure, chronic obstructive pulmonary disease, rheumatoid arthritis, other inflammatory diseases, diabetes and various other conditions. In this review we will concentrate on one type of PDE, mainly PDE5 and its role in pulmonary vascular diseases.

No MeSH data available.


Related in: MedlinePlus